Group B meningococcal vaccine science and policy

J Infect. 2015 Jun:71 Suppl 1:S15-20. doi: 10.1016/j.jinf.2015.04.021. Epub 2015 Apr 24.

Abstract

Capsular group B Neisseria meningitidis is one of the leading causes of death in developed countries. A new vaccine (4CMenB) has recently been developed which was found to have an acceptable safety profile in clinical studies and to be immunogenic. This review examines the evidence supporting the licensure of the 4CMenB vaccine and discusses recommendations for its use.

Keywords: Capsular group B Neisseria meningitidis; Capsular group C Neisseria meningitidis; Children; Immunogenicity; Infant; Reactogenicity; Vaccine.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Infant, Newborn
  • Meningococcal Infections* / epidemiology
  • Meningococcal Infections* / microbiology
  • Meningococcal Infections* / prevention & control
  • Meningococcal Vaccines* / administration & dosage
  • Meningococcal Vaccines* / adverse effects
  • Meningococcal Vaccines* / immunology
  • Middle Aged
  • Neisseria meningitidis, Serogroup B / immunology*
  • Young Adult

Substances

  • 4CMenB vaccine
  • Meningococcal Vaccines